An overview of molecular hybrids in drug discovery
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The hybridization of biologically active molecules is a powerful tool for drug discovery used to target a variety of diseases. It offers the prospect of better drugs for the treatment of a number of illnesses including cancer, malaria, tuberculosis and AIDS. Hybrid drugs can provide combination therapies in a single multi-functional agent and, by doing so, be more specific and powerful than conventional classic treatments. This research field is in great expansion and attracts many researchers worldwide. AREA COVERED: This review covers the main research published between early 2013 to mid-2015 and takes into account several previous reviews on the subject. Its intention is to showcase the most recent advances reported towards the development of molecular hybrids in drug discovery. Particular attention is given to anticancer hybrids throughout the review. EXPERT OPINION: Current advances show that molecular hybrids of biologically active molecules can lead to powerful therapeutics. Natural products play a key role in this field. It is also believed that toxin hybrids present a great opportunity for future progress and should be further explored. Furthermore, the synthesis of hybrid organometallics should be systematically studied as it can lead to potent drugs. The crucial requirement for growth still remains the efficacy of synthesis. Hence, the development of efficient synthetic methods allowing rapid access to diverse series of hybrids must be further investigated by researchers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent Advances in the Biginelli Dihydropyrimidine Synthesis. New Tricks from an Old Dog
Kappe, C. O. (2000) · Accounts of Chemical Research · doi:10.1021/ar000048h · Cited by 1,104
Nepali, K., Sharma, S., Sharma, M., Bedi, P. M. S., & Dhar, K. L. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.03.018 · Cited by 435
Deng, C., Wu, J., Cheng, R., Meng, F., Klok, H.-A., & Zhong, Z. (2014) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2013.10.008 · Cited by 371
Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends: Miniperspective
Zhan, P., Pannecouque, C., De Clercq, E., & Liu, X. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00497 · Cited by 303
A practical view of ‘druggability’
Keller, T. H., Pichota, A., & Yin, Z. (2006) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2006.06.014 · Cited by 295
Advances in the development of hybrid anticancer drugs
Fortin, S., & Bérubé, G. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.798296 · Cited by 223
Self-citationMultifunctional compounds: Smart molecules for multifactorial diseases
Bansal, Y., & Silakari, O. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.01.060 · Cited by 212
Combination of ligand- and structure-based methods in virtual screening
Drwal, M. N., & Griffith, R. (2013) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2013.02.002 · Cited by 209
Ma, L., Zheng, Y., Wang, S., Wang, B., Wang, Z.-R., Pang, L.-P., Zhang, M., Wang, J.-W., Ding, L., Li, J., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00037 · Cited by 168
Taha, M., Ismail, N. H., Lalani, S., Fatmi, M. Q., Atia-tul-Wahab, Siddiqui, S., Khan, K. M., Imran, S., & Choudhary, M. I. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.01.009 · Cited by 165
Hybrid poly(lactic-co-glycolic acid) nanoparticles: design and delivery prospectives
Pandita, D., Kumar, S., & Lather, V. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.09.018 · Cited by 153
Rotili, D., Tomassi, S., Conte, M., Benedetti, R., Tortorici, M., Ciossani, G., Valente, S., Marrocco, B., Labella, D., Novellino, E., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4012802 · Cited by 135
Ye, R., Tan, C., He, L., Chen, M., Ji, L., & Mao, Z. (2014) · Chemical Communications · doi:10.1039/c4cc05215c · Cited by 133
Reiter, C., Fröhlich, T., Zeino, M., Marschall, M., Bahsi, H., Leidenberger, M., Friedrich, O., Kappes, B., Hampel, F., Efferth, T., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.04.053 · Cited by 132
Hybrid Curcumin Compounds: A New Strategy for Cancer Treatment
Teiten, M.-H., Dicato, M. A., & Diederich, M. F. (2014) · Molecules · doi:10.3390/molecules191220839 · Cited by 132
Sangani, C. B., Makawana, J. A., Zhang, X., Teraiya, S. B., Lin, L., & Zhu, H. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.01.018 · Cited by 125
Design and synthesis of novel 1,2,3-triazole-pyrimidine hybrids as potential anticancer agents
Ma, L., Pang, L.-P., Wang, B., Zhang, M., Hu, B., Xue, D., Shao, K., Zhang, B., Liu, Y., Zhang, E., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.08.010 · Cited by 119
Cui, S., Peng, L., Zhang, H., Rasheed, S., Kumar, K. V., & Zhou, C. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.08.063 · Cited by 114
Reiter, C., Fröhlich, T., Gruber, L., Hutterer, C., Marschall, M., Voigtländer, C., Friedrich, O., Kappes, B., Efferth, T., & Tsogoeva, S. B. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.07.048 · Cited by 113
Design and synthesis of novel 1,2,3-triazole–pyrimidine–urea hybrids as potential anticancer agents
Ma, L., Wang, B., Pang, L.-P., Zhang, M., Wang, S., Zheng, Y., Shao, K., Xue, D., & Liu, H. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.12.087 · Cited by 111
Tanaka, Y., Aikawa, K., Nishida, G., Homma, M., Sogabe, S., Igaki, S., Hayano, Y., Sameshima, T., Miyahisa, I., Kawamoto, T., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401170c · Cited by 109
Zhang, X., Kong, Y., Zhang, J., Su, M., Zhou, Y., Zang, Y., Li, J. X., Chen, Y., Fang, Y., Zhang, X., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.03.035 · Cited by 89
Novel hybrid DHPM-fatty acids: Synthesis and activity against glioma cell growth in vitro
Treptow, T. G. M., Figueiró, F., Jandrey, E. H. F., Battastini, A. M. O., Salbego, C. G., Hoppe, J. B., Taborda, P. S., Rosa, S. B., Piovesan, L. A., D’Oca, C. D. R. M., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.03.062 · Cited by 89
Reiter, C., Çapcı, A., Fröhlich, T., Klein, V., Zeino, M., Viertel, K., Held, J., Mordmüller, B. G., Emirdağ, S., Anıl, H., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.01.043 · Cited by 88
Chen, Q.-Y., Liu, Y., & Luesch, H. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200176m · Cited by 84
The discovery of colchicine-SAHA hybrids as a new class of antitumor agents
Zhang, X., Zhang, J., Tong, L., Luo, Y., Su, M., Zang, Y., Li, J. X., Lu, W. P., & Chen, Y. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.03.049 · Cited by 82
DNA Metalating–Intercalating Hybrid Agents for the Treatment of Chemoresistant Cancers
Suryadi, J., & Bierbach, U. (2012) · Chemistry - A European Journal · doi:10.1002/chem.201202050 · Cited by 77
Coumarin derivatives: an updated patent review (2012 – 2014)
Katsori, A., & Hadjipavlou‐Litina, D. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.972368 · Cited by 74
Lagisetti, C., Yermolina, M. V., Sharma, L. K., Palacios, G. F., Prigaro, B. J., & Webb, T. R. (2013) · ACS Chemical Biology · doi:10.1021/cb400695j · Cited by 72
Hua, C., Li, S., Yao, Y., Zhou, L., Zhao, J., Gu, Y., Wang, K., & Li, X. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.07.009 · Cited by 69
Yan, J., Guo, Y., Wang, Y., Mao, F., Huang, L., & Li, X. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.03.030 · Cited by 67
Chen, Q.-Y., Liu, Y., Cai, W., & Luesch, H. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4019965 · Cited by 67
Design, Synthesis and In Vitro Antiproliferative Activity of Novel Isatin‐Quinazoline Hybrids
Farès, M., Eldehna, W. M., Abou‐Seri, S. M., Abdel‐Aziz, H. A., Aly, M. H., & Tolba, M. F. (2015) · Archiv der Pharmazie · doi:10.1002/ardp.201400337 · Cited by 62
Protein–Gold Hybrid Nanocubes for Cell Imaging and Drug Delivery
Ding, H., Yang, D., Zhao, C., Song, Z., Liu, P., Wang, Y., Chen, Z., & Shen, J. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/am5083733 · Cited by 61
Development of Novel ACK1/TNK2 Inhibitors Using a Fragment-Based Approach
Lawrence, H. R., Mahajan, K. N., Luo, Y., Zhang, D., Tindall, N., Huseyin, M. K., Gevariya, H., Kazi, S., Özcan, S., Mahajan, N. P., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501929n · Cited by 60
Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators
Zhan, P., Itoh, Y., Suzuki, T., & Liu, X. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00229 · Cited by 60
Fu, J., Liu, L., Huang, Z., Lai, Y., Ji, H., Peng, S., Tian, J., & Zhang, Y. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400393u · Cited by 60
A review on pharmacophoric designs of antiproliferative agents
Rana, A., Alex, J. M., Chauhan, M., Joshi, G., & Kumar, R. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-1196-5 · Cited by 58
Liu, K., Zhang, D., Chojnacki, J. E., Du, Y., Fu, H., Grant, S., & Zhang, S. (2013) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob40595h · Cited by 58
Synthesis and anti-parasitic activity of a novel quinolinone–chalcone series
Roussaki, M., Hall, B. S., Lima, S. A. C., Cordeiro‐da‐Silva, A., Wilkinson, S. R., & Detsi, A. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.09.047 · Cited by 57
Coumarin chalcone fibrates: A new structural class of lipid lowering agents
Sashidhara, K. V., Palnati, G. R., Sonkar, R., Avula, S. R., Awasthi, C., & Bhatia, G. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.04.026 · Cited by 56
Design, Synthesis, and Evaluation of Fimbrolide–Nitric Oxide Donor Hybrids as Antimicrobial Agents
Kutty, S. K., Barraud, N., Pham, A., Iskander, G., Rice, S. A., Black, D. S., & Kumar, N. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400951f · Cited by 55
The discovery and optimization of novel dual inhibitors of topoisomerase ii and histone deacetylase
Zhang, X., Bao, B., Yu, X., Tong, L., Luo, Y., Huang, Q., Su, M., Li, S., Li, J. X., Zhu, H., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.09.023 · Cited by 52
Cincinelli, R., Musso, L., Dallavalle, S., Artali, R., Tinelli, S., Colangelo, D., Zunino, F., Cesare, M. D., Beretta, G. L., & Zaffaroni, N. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.02.022 · Cited by 51
Vilanova, C., Díaz‐Oltra, S., Murga, J., Falomir, E., Cardá, M., Redondo‐Horcajo, M., Díaz, J. F., Barasoaín, I., & Marco, J. A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501112q · Cited by 50
Design and synthesis of novel indole-chalcone fibrates as lipid lowering agents
Sashidhara, K. V., Dodda, R. P., Sonkar, R., Palnati, G. R., & Bhatia, G. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.04.085 · Cited by 46
Liu, S. V., Tsao-Wei, D. D., Xiong, S., Groshen, S. G., Dorff, T. B., Quinn, D. I., Tai, Y., Engel, J., Hawes, D., Schally, A. V., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0489 · Cited by 45
Chauhan, J. S., Dhanda, S. K., Singla, D., Agarwal, S. M., & Raghava, G. P. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101079 · Cited by 40
Huang, X., Cheng, C. C., Fischmann, T. O., Duca, J. S., Richards, M. P., Tadikonda, P. K., Reddy, P. A., Zhao, L., Siddiqui, M. A., Parry, D., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.02.108 · Cited by 38
Tumour vasculature targeting agents in hybrid/conjugate drugs
Prokopiou, E., Ryder, S. A., & Walsh, J. J. (2013) · Angiogenesis · doi:10.1007/s10456-013-9347-8 · Cited by 38
The Design and Synthesis of a New Class of RTK/HDAC Dual-Targeted Inhibitors
Zhang, X., Su, M., Chen, Y., Li, J. X., & Lu, W. P. (2013) · Molecules · doi:10.3390/molecules18066491 · Cited by 37
Singh, K., Verma, V., Yadav, K., Sreekanth, V., Kumar, D., Bajaj, A., & Kumar, V. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.09.055 · Cited by 36
Kalaria, P. N., Makawana, J. A., Satasia, S. P., Raval, D. K., & Zhu, H. (2014) · MedChemComm · doi:10.1039/c4md00238e · Cited by 36
Fu, J., Liu, L., Huang, Z., Lai, Y., Ji, H., Peng, S., Tian, J., & Zhang, Y. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01778 · Cited by 34
Vilanova, C., Torijano‐Gutiérrez, S., Díaz‐Oltra, S., Murga, J., Falomir, E., Cardá, M., & Marco, J. A. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.09.053 · Cited by 31
Kandi, S. K., Manohar, S., Gerena, C. E. V., Zayas, B., Malhotra, S. V., & Rawat, D. S. (2014) · New Journal of Chemistry · doi:10.1039/c4nj00936c · Cited by 29
Zhou, W., Huang, A., Zhang, Y., Lin, Q., Guo, W., You, Z., Yi, Z., Liu, M., & Chen, Y. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.04.027 · Cited by 25
Romagnoli, R., Baraldi, P. G., Salvador, M. K., Chayah, M., Camacho, M. E., Prencipe, F., Hamel, E., Consolaro, F., Basso, G., & Viola, G. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.05.028 · Cited by 22
Discovery of novel steroidal pyran–oxindole hybrids as cytotoxic agents
Yu, B., Qi, P., Shi, X., Shan, L., Yu, D., & Liu, H. (2014) · Steroids · doi:10.1016/j.steroids.2014.05.022 · Cited by 22
Brossard, D., Zhang, Y., Haider, S. M., Sgobba, M., KHALID, M., Legay, R., Duterque‐Coquillaud, M., Galéra, P., Rault, S., Dallemagne, P., et al. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12195 · Cited by 19
Singh, P., Shaveta, S., Sharma, S., & Bhatti, R. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.11.080 · Cited by 19
Hybrid anticancer 1,2-diazine derivatives with multiple mechanism of action. Part 3 [4,5]
Antoci, V., Amăriucăi-Mantu, D., Cozma, D. G., Usru, C., & Mangalagiu, I. I. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.10.024 · Cited by 18
Nagesh, H. N., Suresh, A., Sirigina, D. S. S. S., Sriram, D., Yogeeswari, P., & Sekhar, K. V. G. C. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.07.067 · Cited by 15
Novel R-roscovitine NO-donor hybrid compounds as potential pro-resolution of inflammation agents
Montanaro, G., Bertinaria, M., Rolando, B., Fruttero, R., Lucas, C. D., Dorward, D. A., Rossi, A. G., Megson, I. L., & Gasco, A. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.01.009 · Cited by 14
Cell-targeted cytotoxics: a new generation of cytotoxic agents for cancer treatment
Bailly, C. (2013) · Phytochemistry Reviews · doi:10.1007/s11101-013-9300-x · Cited by 13
Cited by
Shafiei, M., Peyton, L., Hashemzadeh, M., & Foroumadi, A. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104240 · Cited by 295
Metadata
- Authors
- Bérubé, G.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa Healthcare
- Published
- 2016-01-12
- Volume
- 11
- Issue
- 3
- Pages
- 281-305
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W2255841639
- Cited by
- 338
- References
- 65
- FWCI
- 7.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.